

Announcement Summary

Entity name

PHARMAXIS LTD

Date of this announcement

Friday December 02, 2022

The +securities the subject of this notification are:

♥ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	NED Options	9,000,000	02/12/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

Registration number

ABN

75082811630

1.3 ASX issuer code

PXS

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

2/12/2022



Part 2 - Issue details

- 2.1 The +securities the subject of this notification are:
- € +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
- 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code +Security description

New class - code to be confirmed NED Options

ISIN code

Options

+Security type

Date the +securities the subject of this notification were issued

2/12/2022

Will all the +securities issued in this class rank equally in all respects from their issue date?

✓ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?
⊗ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Malcolm McComas	Bunyula Super Fund Pty Ltd (Bunyula Super Fund a/c)	3,000,000
Neil Graham	Biopharma Medicines Pharma LLC	3,000,000
Kathleen Metters	same	3,000,000

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

☑ No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.


https://www.pharmaxis.com.au/assets/Documents/pdf/02022/ASX/2022-10-28-PXS-Notice-of-AGM-2022.pdf

Options Details

+Security currency Exercise price Expiry dateAUD - Australian Dollar AUD 0.11000000 1/12/2027

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other





_								
I)	Δ	c	r	r	ın	ıŧı	n	n

Pharmaxis Ordinary Shares

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

https://www.pharmaxis.com.au/assets/Documents/pdf/02022/ASX/2022-10-28-PXS-Notice-of-AGM-2022.pdf

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue details

Number of +securities

9,000,000



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description

Total number of +securities on issue

PXS: ORDINARY FULLY PAID

634,602,030

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description

Total number of +securities on issue

PXSAAP: OPTION EXPIRING 06-JUN-2023 EX NIL PRICE

66,500

PXSAAS: PERFORMANCE RIGHTS

29,872,075

New class - code to be confirmed : NED Options

9,000,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? ☑ No

5.2a Date of meeting or proposed meeting to approve the issue under listing rule **7.1** 29/11/2022